International Myeloma Society

International Myeloma Society
Name	International Myeloma Society
Type	Nonprofit organization
Founded	1999
Headquarters	Unknown
Leader title	President

International Myeloma Society The International Myeloma Society is a global professional association focused on plasma cell disorders, coordinating clinicians, researchers, and patient advocates to improve outcomes for people with multiple myeloma, solitary plasmacytoma, and related conditions. It collaborates with major cancer centers, academic institutions, regulatory agencies, pharmaceutical companies, and patient organizations to advance research, standardize care, and disseminate clinical practice guidance.

History

The organization was established in the late 1990s amid growing international collaboration in hematology and oncology, intersecting with institutions such as Mayo Clinic, Dana–Farber Cancer Institute, MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, and Stanford University School of Medicine. Early meetings attracted participants from National Cancer Institute, European Hematology Association, American Society of Hematology, International Myeloma Working Group, and academic centers including University of Oxford, University of Cambridge, Imperial College London, Karolinska Institutet, University of Vienna, and University of Toronto. Founding figures and contributors often had affiliations with research networks like European Research Council, Wellcome Trust, National Institutes of Health, Cancer Research UK, and foundations such as Leukemia & Lymphoma Society. The Society’s evolution reflected seminal clinical trials and drug approvals involving agents developed by companies such as Janssen Pharmaceuticals, Celgene, Bristol-Myers Squibb, Amgen, and Takeda Pharmaceutical Company. Milestones paralleled landmark publications in journals including The New England Journal of Medicine, The Lancet Oncology, Blood (journal), Journal of Clinical Oncology, and Nature Medicine.

Mission and Objectives

The Society’s mission emphasizes improving diagnosis, treatment, and survivorship through multidisciplinary collaboration with entities like World Health Organization, European Commission, U.S. Food and Drug Administration, European Medicines Agency, and patient advocacy groups such as Myeloma UK, International Myeloma Foundation, Leukemia & Lymphoma Society (LLS), and National Comprehensive Cancer Network. Objectives include developing consensus guidelines in conjunction with academic bodies like American Society of Clinical Oncology, promoting translational science with partners like Broad Institute, facilitating clinical trials through consortia such as EORTC and National Clinical Trials Network, and advancing education via collaborations with universities like Harvard Medical School and Johns Hopkins University.

Organizational Structure and Membership

Governance typically features an elected executive committee, scientific advisory boards, and regional chapters interfacing with institutions such as University College London, University of Heidelberg, Seoul National University, Peking University, University of São Paulo, and University of Cape Town. Membership comprises hematologists, oncologists, pathologists, radiologists, translational scientists, nursing leaders, and patient advocates affiliated with hospitals like Cleveland Clinic, Mount Sinai Hospital (New York), Royal Marsden Hospital, St. Bartholomew's Hospital, Children's Hospital of Philadelphia, and research centers including Fred Hutchinson Cancer Center and Institute of Cancer Research. The Society liaises with specialty organizations such as International Society of Hematology, European Society for Medical Oncology, Asia Pacific Hematology Consortium, and regional cancer networks.

Activities and Programs

Programs span guideline development, multicenter trial facilitation, registries, patient education, and professional training in partnership with bodies like World Federation of Hemophilia for rare disorders, International Agency for Research on Cancer, and philanthropic organizations such as Bill & Melinda Gates Foundation and Howard Hughes Medical Institute. The Society supports registries and biobanks connecting centers like Hospital Clínic de Barcelona, St. Jude Children's Research Hospital, Pitié-Salpêtrière Hospital, and Guy's and St Thomas' NHS Foundation Trust. Educational initiatives have included webinars, fellowships, and mentorship programs working with academic centers including Yale School of Medicine, Columbia University Irving Medical Center, King's College London, and Monash University. Quality-improvement collaboratives have drawn on experiences from Institute for Healthcare Improvement and policy frameworks from Organisation for Economic Co-operation and Development.

Research, Guidelines, and Education

The Society promotes basic, translational, and clinical research across molecular biology, immunotherapy, stem cell transplantation, and supportive care, engaging laboratories at Cold Spring Harbor Laboratory, Sanger Institute, Max Planck Institute for Molecular Genetics, and Ragon Institute. It contributes to consensus statements and clinical practice guidelines alongside groups like International Myeloma Working Group, European Society for Blood and Marrow Transplantation, and American Society for Transplantation and Cellular Therapy. Educational outputs include curriculum modules referenced by medical schools such as UCL Medical School and continuing medical education endorsed by organizations like Royal College of Physicians, American Board of Internal Medicine, and European Board for Accreditation in Hematology.

Conferences and Meetings

Annual and biennial congresses convene clinicians and scientists from networks including ASH Annual Meeting, ESMO Congress, ASCO Annual Meeting, European Hematology Association Congress, and regional meetings hosted at venues in cities like Paris, New York City, London, Tokyo, São Paulo, Cape Town, and Geneva. Meetings feature plenary sessions, workshops, and poster sessions with participation from investigators who have presented at forums such as AACR Annual Meeting, SITC Annual Meeting, Gordon Research Conferences, and Cold Spring Harbor Meetings. Collaborative symposia often include representatives from regulatory forums like FDA Oncology Center of Excellence and funding bodies such as National Cancer Institute and European Research Council.

Category:Hematology organizations